New drug trial targets lingering COVID symptoms
NCT ID NCT07123727
Summary
This study is testing whether a drug called Anktiva is safe for people with Long COVID—persistent symptoms that continue after the initial infection has cleared. The trial will enroll 40 adults who have had bothersome Long COVID symptoms for at least 60 days. Researchers will closely monitor participants for any side effects while tracking changes in their symptoms and immune cell counts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chan Soon-Schiong Institute for Medicine (CSSIFM)
RECRUITINGEl Segundo, California, 90245, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.